PPARα polymorphisms as risk factors for dyslipidemia in a Brazilian population

Molecular Genetics and Metabolism

Volumn 102, Issue 2, 2011, Pages 189-193

  Mazzotti, Diego Robles ^a   Singulane, Cristiane Carvalho ^b   Ota, Vanessa Kiyomi ^a   Rodrigues, Thiago Potrich ^b   Furuya, Tatiane Katsue ^a   de Souza, Fernando José ^b   Cordeiro, Bruna Grassiela ^b   Magalhães, Camila ^b   Chen, Elizabeth Suchi ^a   Jacomini, Anielli ^b   Smith, Marilia de Arruda Cardoso ^a   Borsatto Galera, Bianca ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CUIABÁ   (Brazil)

^c UNIVERSIDADE FEDERAL DE MATO GROSSO   (Brazil)

Author keywords

Dyslipidemia; Genetic association; Haplotype; Intron 7; L162V; Polymorphism; PPAR

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BRAZIL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA EXTRACTION; DYSLIPIDEMIA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; INTERVIEW; INTRON; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WAIST HIP RATIO;

AGED; AGED, 80 AND OVER; BRAZIL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; RISK FACTORS;

EID: 78651431686     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.11.156     Document Type: Article

References (31)

1. Lechleitner M. Obesity and the metabolic syndrome in the elderly - a mini-review. Gerontology 2008, 54:253-259.
2. Shah A., Rader D.J., Millar J.S. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010, 210:35-40.
3. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol. 2000, 86:943-949.
4. Chen E.S., Mazzotti D.R., Furuya T.K., Cendoroglo M.S., Ramos L.R., Araujo L.Q., Burbano R.R., Smith Mde A. Association of PPARalpha gene polymorphisms and lipid serum levels in a Brazilian elderly population. Exp. Mol. Pathol. 2010, 88:197-201.
5. Prieur X., Coste H., Rodriguez J.C. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J. Biol. Chem. 2003, 278:25468-25480.
6. Yong E.L., Li J., Liu M.H. Single gene contributions: genetic variants of peroxisome proliferator-activated receptor (isoforms alpha, beta/delta and gamma) and mechanisms of dyslipidemias. Curr. Opin. Lipidol. 2008, 19:106-112.
7. Fruchart J.C. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009, 205:1-8.
8. Lacquemant C., Lepretre F., Pineda Torra I., Manraj M., Charpentier G., Ruiz J., Staels B., Froguel P. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diab. Metab. 2000, 26:393-401.
9. Vohl M.C., Lepage P., Gaudet D., Brewer C.G., Betard C., Perron P., Houde G., Cellier C., Faith J.M., Despres J.P., Morgan K., Hudson T.J. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J. Lipid Res. 2000, 41:945-952.
10. Ewing J.A. Detecting alcoholism. The CAGE questionnaire. Jama 1984, 252:1905-1907.
11. Matsudo S., Araujo T., Matsudo V., Andrade D., Andrade E., Oliveira L.C. Questionário Internacional de Atividade Física (IPAQ): estudo de validade e reprodutibilidade no Brasil. Rev Bras Ativ Fis e Saúde 2001, 6:5-18.
12. Whitworth J.A. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 2003, 21:1983-1992.
13. The DECODE study group Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Diabetologia 1999, 42:647-654.
14. Santos R.D. Diretrizes Brasileiras sobre dislipidemias e diretriz de prevenção de aterosclerose. Arq. Bras. Cardiol. 2001, 3:1-48.
15. Yesavage J.A., Brink T.L., Rose T.L., Lum O., Huang V., Adey M., Leirer V.O. Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res. 1982, 17:37-49.
16. Lahiri D.K., Nurnberger J.I. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991, 19:5444.
17. Brune S., Kolsch H., Ptok U., Majores M., Schulz A., Schlosser R., Rao M.L., Maier W., Heun R. Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease. J. Neural Transm. 2003, 110:1041-1050.
18. Ding K., Zhou K., He F., Shen Y. LDA-a java-based linkage disequilibrium analyzer. Bioinformatics (Oxford, England) 2003, 19:2147-2148.
19. Sole X., Guino E., Valls J., Iniesta R., Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics (Oxford, England) 2006, 22:1928-1929.
20. Purcell S., Cherny S.S., Sham P.C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics (Oxford, England) 2003, 19:149-150.
21. Doney A.S., Fischer B., Lee S.P., Morris A.D., Leese G., Palmer C.N. Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study. Nucl. Recept. 2005, 3:4.
22. Tai E.S., Collins D., Robins S.J., O'Connor J.J., Bloomfield H.E., Ordovas J.M., Schaefer E.J., Brousseau M.E. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 2006, 187:153-160.
23. Volcik K.A., Nettleton J.A., Ballantyne C.M., Boerwinkle E. Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. Am. J. Clin. Nutr. 2008, 87:1926-1931.
24. Lopez-Sall P., Bard J.M., Nazih H., Cisse A., Bobin-Dubigeon C., Sall N.D. PPAR alpha-L162V, frequency and relationship with type 2 diabetes among black Senegalese people. Annales de biologie clinique 2008, 66:475-477.
25. Flavell D.M., Ireland H., Stephens J.W., Hawe E., Acharya J., Mather H., Hurel S.J., Humphries S.E. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes 2005, 54:582-586.
26. Jamshidi Y., Montgomery H.E., Hense H.W., Myerson S.G., Torra I.P., Staels B., World M.J., Doering A., Erdmann J., Hengstenberg C., Humphries S.E., Schunkert H., Flavell D.M. Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation 2002, 105:950-955.
27. National Center for Biotechnology Information, Reference SNP(refSNP) Cluster Report: rs4253778 2009.
28. Krawiec A., Cylwik B., Chrostek L., Supronowicz Z., Szmitkowski M. The effect of chronic alcohol abuse on the lipids, lipoproteins and apolipoproteins concentrations in the sera. Pol Merkur Lekarski 2008, 24:521-525.
29. Robitaille J., Brouillette C., Houde A., Lemieux S., Perusse L., Tchernof A., Gaudet D., Vohl M.C. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J. Hum. Genet. 2004, 49:482-489.
30. Flavell D.M., Jamshidi Y., Hawe E., Pineda Torra I., Taskinen M.R., Frick M.H., Nieminen M.S., Kesaniemi Y.A., Pasternack A., Staels B., Miller G., Humphries S.E., Talmud P.J., Syvanne M. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002, 105:1440-1445.
31. Zak I., Balcerzyk A., Sarecka B., Niemiec P., Ciemniewski Z., Dylag S. Contemporaneous carrier-state of two or three "proatherosclerotic" variants of APOE, ICAM1, PPARA and PAI-1 genes differentiate CAD patients from healthy individuals. Clin. Chim. Acta 2005, 362:110-118.